Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant apalutamide versus standard of care after radical prostatectomy in high-risk localized or locally advanced prostate cancer
2024-511832-29-00Phase 2Authorised
- Sponsor
- Universität Münster
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in prostate adenocarcinoma comparing Apalutamide with Standard of care (2 arms). Primary endpoint: Progression-free survival. Planned start Aug 2020; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2024-511832-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511832-29-00.